D. Choquette

发表

Structure-based design of novel class II c-Met inhibitors: 2. SAR and kinase selectivity profiles of the pyrazolone series.

D. Whittington, Matthew R. Lee, C. Dominguez, 2012, Journal of medicinal chemistry.

Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase.

K. Rex, K. Shah, Douglas Hoffman, 2008, Journal of medicinal chemistry.

Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.

K. Rex, K. Shah, S. Bellon, 2009, Bioorganic & medicinal chemistry letters.

Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors.

A. Coxon, D. Whittington, A. Tasker, 2008, Journal of medicinal chemistry.

Discovery of AMG 458: A Potent, Selective, and Orally Bioavailable c-Met Inhibitor

K. Rex, Matthew R. Lee, S. Bellon, 2008 .

Discovery of novel 1,2,3,4-tetrahydroisoquinolines and 3,4-dihydroisoquinoline-1(2H)-ones as potent and selective inhibitors of KDR: synthesis, SAR, and pharmacokinetic properties.

A. Polverino, J. Harmange, Y. Teffera, 2008, Bioorganic & medicinal chemistry letters.

VX-322: a novel dual receptor tyrosine kinase inhibitor for the treatment of acute myelogenous leukemia.

Jiehua Zhou, G. Henkel, Yung-mae M. Yao, 2012, Journal of medicinal chemistry.

Design, synthesis, and evaluation of a novel dual FMS-like tyrosine kinase 3/stem cell factor receptor (FLT3/c-KIT) inhibitor for the treatment of acute myelogenous leukemia.

V. Galullo, G. Henkel, J. Ma, 2011, Journal of medicinal chemistry.

Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.

Ling Wang, Kelly Regal, Sesha Neervannan, 2008, Journal of medicinal chemistry.

Syntheses, structures, and isomerization processes of dialkylaluminum silylamido complexes

R. Planalp, D. Choquette, K. J. Ahmed, 1992 .

Thermolysis of halo- and alkylaluminum silylamido complexes and the Al4N4 cubane core structure of [iso-BuAlNSiPh3]4

R. Planalp, M. Olmstead, D. Choquette, 1993 .

Synthesis and reactivity of cyclopentadienyltitanium complexes of the polydentate alkoxide ligand cis-1,3,5-cyclohexanetrialkoxide

R. Planalp, D. Choquette, R. Graceffa, 1995 .

The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer.

Karina Romero, Renee Emkey, Hao Chen, 2012, Journal of medicinal chemistry.

In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models

K. Rex, A. Coxon, M. Damore, 2016, Molecular Cancer Therapeutics.

Abstract 728: AMG 337, a novel, potent and selective MET kinase inhibitor, has robust growth inhibitory activity in MET-dependent cancer models

K. Rex, A. Coxon, R. Radinsky, 2014 .

Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity.

K. Rex, A. Coxon, D. Whittington, 2016, Journal of medicinal chemistry.

Discovery of potent and selective 8-fluorotriazolopyridine c-Met inhibitors.

K. Rex, D. Whittington, S. Bellon, 2015, Journal of medicinal chemistry.

Discovery and optimization of a potent and selective triazolopyridinone series of c-Met inhibitors.

K. Rex, D. Whittington, S. Bellon, 2012, Bioorganic & Medicinal Chemistry Letters.

Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibitors.

T. Bush, A. Cheng, P. Andrews, 2012, Bioorganic & medicinal chemistry letters.

Abstract 1795: Characterization of a novel series of potent, selective inhibitors of wild type and mutant/fusion anaplastic lymphoma kinase

D. Whittington, P. Andrews, K. Wilcoxen, 2012 .

Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.

K. Rex, K. Shah, S. Bellon, 2009, Bioorganic & medicinal chemistry letters.